FO
ITCI

FT Options’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

FT Options’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-18,000
Closed -$359K – 399
2016
Q3 		$359K Buy
+18,000
New +$728K 0.28% 70

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FT Options's ITCI Position: Q4 2016 in Review

FT Options sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2016, closing a stake of 4,800 shares — an estimated $73K sold.

FT Options first reported a position in ITCI in Q3 2016 and held it in 1 quarter. The position peaked at $73K in Q3 2016. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

  • FT Options reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2016 after selling out during the quarter.
  • FT Options sold 4,800 Intra-Cellular Therapies Inc. shares in Q4 2016, an estimated $73K.
  • FT Options first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 1 quarter.
  • FT Options's Intra-Cellular Therapies Inc. position peaked at $73K in Q3 2016.
  • 129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on FT Options's 13F filing for Q4 2016, filed 10 Feb 2017.